TRIB Trinity Biotech PLC ADS

Trinity Biotech plc to Announce Q4 and Fiscal Year 2023 Financial Results

Trinity Biotech plc to Announce Q4 and Fiscal Year 2023 Financial Results

Conference Call Scheduled for Thursday, April 4, 2024 at 8:00 AM ET

DUBLIN, Ireland, March 28, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB) (the “Company”), a leading developer and manufacturer of diagnostic solutions for the point-of-care and clinical laboratory markets, will report financial results for the fourth quarter and fiscal year 2023 on Thursday, April 4, 2024 at 8:00 AM ET.

Conference Call Dial-In & Webcast Information

Date:Thursday, April 4, 2024
Time:8:00 AM ET
United States:1-877-407-0784
International:1-201-689-8560
Conference ID:13745604
Call me™:
Webcast
  

About Trinity Biotech

Trinity Biotech develops, acquires, manufactures and markets diagnostic systems, including both reagents and instrumentation, for the point-of-care and clinical laboratory segments of the diagnostic market. The products are used to detect infectious diseases and to quantify the level of Haemoglobin A1c and other chemistry parameters in serum, plasma and whole blood. Trinity Biotech sells direct in the United States, Germany, France and the U.K. and through a network of international distributors and strategic partners in over 75 countries worldwide. For further information, please see the Company's website: .

Contact:Trinity Biotech plc

Des Fitzgerald 

(353)-1-2769800

LifeSci Partners, LLC

Eric Ribner

(1)-646-751-4363

E-mail



EN
28/03/2024

Underlying

TRIBTrinity Biotech PLC ADS

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Trinity Biotech PLC ADS

 PRESS RELEASE
Free
TRIB Trinity Biotech...

Trinity Biotech Announces Fourth Quarter and Fiscal Year 2023 Financia...

Trinity Biotech Announces Fourth Quarter and Fiscal Year 2023 Financial Results & Business Updates DUBLIN, Ireland, April 04, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial stage biotechnology company focused on diabetes management solutions and human diagnostics, including wearable biosensors, today announced results for the quarter ended December 31, 2023 and fiscal year 2023 and key business updates. Business Updates Comprehensive Transformation Plan At the Emerging Growth Investor Conference on March 7, 2024, our new management team announced a com...

April 4, 2024 1 EN
 PRESS RELEASE
Free
TRIB Trinity Biotech...

Trinity Biotech plc to Announce Q4 and Fiscal Year 2023 Financial Resu...

Trinity Biotech plc to Announce Q4 and Fiscal Year 2023 Financial Results Conference Call Scheduled for Thursday, April 4, 2024 at 8:00 AM ET DUBLIN, Ireland, March 28, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB) (the “Company”), a leading developer and manufacturer of diagnostic solutions for the point-of-care and clinical laboratory markets, will report financial results for the fourth quarter and fiscal year 2023 on Thursday, April 4, 2024 at 8:00 AM ET. Conference Call Dial-In & Webcast Information Date:Thursday, April 4, 2024Time:8:00 AM ETUnited States:1-877-4...

March 28, 2024 1 EN
 PRESS RELEASE
Free
TRIB Trinity Biotech...

Trinity Biotech Regains Compliance with Nasdaq Minimum Closing Bid Pri...

Trinity Biotech Regains Compliance with Nasdaq Minimum Closing Bid Price Rule DUBLIN, Ireland, March 08, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech Plc. (NASDAQ: TRIB) (the “Company”) today reported the receipt of a formal notification from The Nasdaq Stock Market LLC ("Nasdaq") that the Company has regained compliance with Listing Rule 5450(a)(1), which requires the Company's American Depositary Shares (“ADSs”) to maintain a minimum bid price of $1.00 per ADS. The Nasdaq staff made this determination of compliance after the closing bid price of the Company's was at $1.00 per share or great...

March 8, 2024 1 EN
 PRESS RELEASE
Free
TRIB Trinity Biotech...

Trinity Biotech Plc Finalizes Effective Date of ADS Ratio Change

Trinity Biotech Plc Finalizes Effective Date of ADS Ratio Change DUBLIN, Ireland, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech Plc.(NASDAQ: TRIB) (the “Company”) today announced that it has finalized the effective date of its ratio change of its American depositary shares (“ADSs”) from one (1) ADS representing four (4) Class A ordinary shares to one (1) ADS representing twenty (20) Class A ordinary shares. The effect of the ratio change on the ADS trading price on the Nasdaq Global Market is expected to take place at the open of trading on February 23, 2024 (U.S. Eastern Time) (the “...

February 15, 2024 1 EN
 PRESS RELEASE
Free
TRIB Trinity Biotech...

Trinity Biotech Plc Announces Plan to Implement ADS Ratio Change

Trinity Biotech Plc Announces Plan to Implement ADS Ratio Change DUBLIN, Ireland, Feb. 13, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech Plc.(NASDAQ: TRIB) (the “Company”) today announced that it plans to change the ratio of the American depositary shares (“ADSs”) representing its Class A ordinary shares from one (1) ADS representing four (4) Class A ordinary share to one (1) ADS representing twenty (20) Class A ordinary shares. For Trinity Biotech Plc ADS holders, the change in the ADS ratio will have the same effect as a one-for-five reverse ADS split and is intended to i) enable the Compan...

February 13, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch